Related Experiment Video
Updated: May 5, 2026
07:46
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
5.2K
MODELING DRUG-ORGAN INTERACTIONS AND OPTIMIZING IMMUNOTHERAPY: A QUANTITATIVE SYSTEMS PHARMACOLOGY AND ODRONEXTAMAB
11Department of Pharmacology and Toxicology, Faculty of Pharmacy, AlFarahidi University, Iraq.
Georgian Medical News
|October 10, 2025
Summary
Quantitative Systems Pharmacology (QSP) modeling optimized cardiorenal medications and odronextamab dosing for B-cell non-Hodgkin lymphoma (B-NHL) patients. This approach enhances drug efficacy and minimizes inflammatory responses by understanding drug mechanisms.
Area of Science:
- Pharmacology
- Computational Biology
- Oncology
Background:
- Cardiovascular and renal diseases are significant global health issues.
- B-cell non-Hodgkin lymphoma (B-NHL) presents treatment challenges.
- Odronextamab, a bispecific antibody, shows promise but is limited by dosing-related inflammatory responses.
- Quantitative Systems Pharmacology (QSP) modeling can offer mechanistic insights and optimize dosing.
Purpose of the Study:
- To computationally model mechanisms of cardiorenal medications and optimize their dosing.
- To identify optimal odronextamab dosing regimens for B-NHL patients to improve efficacy and minimize inflammatory responses.
Main Methods:
- Developed a QSP framework using secondary data, integrating physiological, pharmacokinetic, and pharmacodynamic parameters.
- Simulated renal and cardiovascular impacts of medications using variables like blood pressure and glomerular filtration rate.
- Evaluated odronextamab dosing regimens based on interleukin-6 (IL-6) responses and validated model predictions against real-world data.
Main Results:
- Cardiorenal medications improved blood pressure and ejection fraction.
- Identified covert salt loss as a mechanism, alongside sugar and water excretion, improving renal regulation.
- Group C (variable dosing) showed the most favorable IL-6 reduction for odronextamab, leading to a proposed refined split-dose schedule.
Conclusions:
- Mechanistic insights into cardiorenal medication effects via salt, sugar, and water modulation were provided.
- A validated, optimized odronextamab dosing strategy was presented, reducing IL-6 levels and enhancing safety in B-NHL patients.
- Integrated QSP with real-world data supports personalized pharmacotherapy and highlights computational modeling's value in drug development.
Related Concept Videos
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
268
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
268
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
129
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
129
01:27Pharmacodynamic Models: Overview
161
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
161
01:18Pharmacodynamic Models: Emax Drug–Concentration Effect Model
245
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
245
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
157
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
157
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97